US 12,435,143 B2
Caninized antibodies against canine CTLA-4
Mohamad Morsey, Omaha, NE (US); Yuanzheng Zhang, Somerset, NJ (US); and Ian Tarpey, St. Ives (GB)
Assigned to INTERVET INC., Rahway, NJ (US)
Appl. No. 17/626,239
Filed by Intervet Inc., Madison, NJ (US)
PCT Filed Jul. 15, 2020, PCT No. PCT/EP2020/069923
§ 371(c)(1), (2) Date Jan. 11, 2022,
PCT Pub. No. WO2021/009187, PCT Pub. Date Jan. 21, 2021.
Claims priority of provisional application 63/048,873, filed on Jul. 7, 2020.
Claims priority of provisional application 62/926,047, filed on Oct. 25, 2019.
Claims priority of provisional application 62/874,287, filed on Jul. 15, 2019.
Prior Publication US 2022/0251208 A1, Aug. 11, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 2039/505 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An isolated mammalian antibody or an antigen binding fragment thereof that binds canine Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) and blocks the binding of canine CTLA-4 with canine CD80, blocks the binding of canine CTLA-4 with canine CD86, or blocks both the binding of canine CTLA-4 with canine CD80 and the binding of canine CTLA-4 with canine CD86;
wherein said antibody or antigen binding fragment thereof comprises:
(a) a light chain variable region (VL) complementarity-determining region (CDR)-1 comprising the amino acid sequence of SEQ ID NO: 92;
(b) a VLCDR-2 comprising the amino acid sequence of SEQ ID NO: 94;
(c) a VLCDR-3 comprising the amino acid sequence of SEQ ID NO: 96;
(d) a heavy chain variable region (VH) CDR-1 comprising the amino acid sequence of SEQ ID NO: 86;
(e) a VHCDR-2 comprising the amino acid sequence of SEQ ID NO: 88; and
(f) a VHCDR-3 comprising the amino acid sequence of SEQ ID NO: 90.